---
title: Magnetic stimulation reduces involuntary jerks
nct_id: NCT06570824
phase: NA
status: RECRUITING
sponsor: Danish Research Centre for Magnetic Resonance
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06570824"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06570824"
last_fetched: "2026-05-10T14:08:11.816Z"
source: "Parkinson's Pathways (curated)"
---
# Magnetic stimulation reduces involuntary jerks

**Goal (in five words):** Magnetic stimulation reduces involuntary jerks

**Official Title:** Network Based Repetitive Transcranial Magnetic Stimulation (rTMS) as an Intervention for Levodopa-induced Dyskinesia (LID) in Parkinson's Disease (PD)

**Trial ID:** [NCT06570824](https://clinicaltrials.gov/study/NCT06570824)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Danish Research Centre for Magnetic Resonance
- **Target Enrollment:** 68 participants
- **Start Date:** 2024-07-22
- **Completion Date:** 2027-05-01
- **Conditions:** Dyskinesia, Drug-Induced, Parkinson Disease
- **Interventions:** active TMS, sham TMS
- **Intervention Types:** DEVICE

## Summary For Families

They're testing whether targeted magnetic stimulation can reduce the involuntary jerks and writhing that happen at levodopa's peak, the peak-of-dose dyskinesia that many people with Parkinson's find disabling. The approach uses network-based repetitive transcranial magnetic stimulation, delivering brief magnetic pulses to modulate overactive brain circuits that drive dyskinesia, comparing active versus sham stimulation; it does not change your levodopa but aims to dampen the abnormal motor signals. The trial seeks people aged 18 to 80 with clinically established or probable Parkinson's who have peak-of-dose dyskinesia and have been on stable Parkinson medications for at least four weeks. People with epilepsy or seizure risk, certain psychiatric conditions, regular benzodiazepine or opioid use, use of antipsychotics, Donepezil or GABAergic drugs, MRI contraindications, or women who are pregnant or not using contraception are excluded, and participants must consent to be informed about any incidental health findings.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Clinically established or probable PD
* Clinical Diagnostic Criteria for Parkinson's Disease
* Peak-of-dose levodopa-induced dyskinesia.
* Stable antiparkinsonian medicine for at least four weeks.
* Signed informed consent.

Exclusion Criteria:

* Psychiatric disorders.
* Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin).
* Regular usage of benzodiazepines and opioids (more than once per week).
* History of neurological disease other than Parkinson's disease.
* History of epilepsy/conditions associated with increased risk to seizure-induction through TMS.
* Close relatives suffering from epilepsy/conditions associated with increased risk to seizure-induction through TMS.
* Contraindications for MRI scan
* Female participants of childbearing age must not be pregnant and that they must use contraception during the trial.
* Refuse to be informed about new health related information and accidental health related findings that might appear through participation in the study.
```

## Locations (1)

- DRCMR, Hvidovre, Denmark _(55.6430, 12.4771)_
  - Hartwig Siebner, Prof — (CONTACT)

## Central Contacts

- Laura Sakalauskaite, MD — (CONTACT) — +45 38621184 — laura.sakalauskaite.01@regionh.dk

---

*Canonical: https://parkinsonspathways.com/trial/NCT06570824*  
*HTML version: https://parkinsonspathways.com/trial/NCT06570824*  
*Source data: https://clinicaltrials.gov/study/NCT06570824*